https://www.theverge.com/2022/7/11/23204111/twitter-unmentioning-all-users-leave-conversation-thread?utm_campaign=theverge&utm_content=chorus&utm_medium=social&utm_source=twitter
Lineage Cell Therapeutics Announces OpRegen Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured At 2024 Retinal Cell & Gene Therapy Innovation Summit
BCVA gains of +5.5 letters at 24 months in Cohort 4 patients (n=10)BCVA gains of +7.4 letters among Cohort 4 patients with extensive OpRegen bleb coverage of the GA lesion (n=5)Maintenance or increases in external